Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Depression: Overview01:18

Depression: Overview

656
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
656
Long-term Depression01:03

Long-term Depression

2.9K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
2.9K
Long-term Depression01:05

Long-term Depression

32.8K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
32.8K
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

346
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
346
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

432
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
432
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.2K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Question: Why Is My Patient With Breast Cancer Advised That She Can Take Clozapine and Tamoxifen Together Despite Possible Interactions Between the Two?

Journal of clinical psychopharmacology·2026
Same author

Nathan S. Kline: From the first treatments of psychosis and depression, a 70-year legacy of a pioneer of psychopharmacology.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Karl Rickels, MD: A 100-Year Journey.

Journal of clinical psychopharmacology·2026
Same author

Question: How Is it Possible That Phenelzine Combined With Dextromethorphan Could Cause Serotonin Syndrome?

Journal of clinical psychopharmacology·2026
Same author

Time Trends in Prescribing of Anxiolytic, Sedative, and Hypnotic Drugs in the United States.

Clinical therapeutics·2026
Same author

Question: Should I be Advising My Patients to Drink More Lithium-Containing Bottled Water to Possibly Prevent Alzheimer Disease?

Journal of clinical psychopharmacology·2025

Related Experiment Video

Updated: Dec 18, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

434

COVID-19, interferons, and depression: A commentary.

Richard I Shader1

  • 1Departments of Immunology and Psychiatry, Tufts University School of Medicine, Boston, United States.

Psychiatry Research
|June 15, 2020
PubMed
Summary
This summary is machine-generated.

Interferons (INFs) used for COVID-19 treatment may lower tryptophan levels, potentially causing depression. Augmenting tryptophan through diet or supplements is recommended for patients on INFs.

Keywords:
COVID-19DepressionInterferonsKynurenine

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.7K
A New Method for Inducing a Depression-Like Behavior in Rats
07:57

A New Method for Inducing a Depression-Like Behavior in Rats

Published on: February 22, 2018

21.8K

Related Experiment Videos

Last Updated: Dec 18, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

434
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.7K
A New Method for Inducing a Depression-Like Behavior in Rats
07:57

A New Method for Inducing a Depression-Like Behavior in Rats

Published on: February 22, 2018

21.8K

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Interferons (INFs) are explored for COVID-19 treatment.
  • INFs alter tryptophan (TRP) metabolism, reducing its role in serotonin synthesis.

Purpose of the Study:

  • To discuss the metabolic pathway linking INFs to depression.
  • To recommend strategies for managing potential depressive side effects in COVID-19 patients treated with INFs.

Main Methods:

  • Review of the biochemical pathway of tryptophan metabolism.
  • Clinical observation of potential mood alterations in patients receiving INFs.

Main Results:

  • INF treatment can deplete TRP levels, impacting serotonin production.
  • Reduced TRP may trigger or worsen depression in susceptible individuals.

Conclusions:

  • COVID-19 patients treated with INFs may be at risk for depression due to TRP metabolism changes.
  • In-hospital tryptophan augmentation via diet or supplements is advised.
  • Selective serotonin reuptake inhibitors are a potential treatment for persistent depressive symptoms.